Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.
For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with blinatumomab, a CD19/CD3 bispecific antibody construct (BiTE®), or with chimeric antigen receptor T cells (CAR-T) has shown great promise for t...
Main Authors: | Sandra L Ross, Marika Sherman, Patricia L McElroy, Julie A Lofgren, Gordon Moody, Patrick A Baeuerle, Angela Coxon, Tara Arvedson |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5570333?pdf=render |
Similar Items
-
Aspects of the mode of action of bispecific T cell engager (BiTE) antibodies
by: Hauff, Cornelia
Published: (2009) -
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
by: Regina Jitschin, et al.
Published: (2018-11-01) -
Arming oncolytic viruses with bispecific T cell engagers (BiTEs) for expression and secretion into the tumour microenvironment
by: Freedman, Joshua
Published: (2017) -
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
by: Maciej Kujawski, et al.
Published: (2019-09-01) -
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
by: Hui Yang, et al.
Published: (2020-11-01)